volume 11 issue 8 pages 2566-2578

Pluronics and MDR Reversal: An Update

Publication typeJournal Article
Publication date2014-07-10
scimago Q1
wos Q1
SJR0.968
CiteScore7.8
Impact factor4.5
ISSN15438384, 15438392
PubMed ID:  24950236
Drug Discovery
Pharmaceutical Science
Molecular Medicine
Abstract
Multidrug resistance (MDR) remains one of the biggest obstacles for effective cancer therapy. Currently there are only few methods that are available clinically that are used to bypass MDR with very limited success. In this review we describe how MDR can be overcome by a simple yet effective approach of using amphiphilic block copolymers. Triblock copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), arranged in a triblock structure PEO-PPO-PEO, Pluronics or “poloxamers”, raised a considerable interest in the drug delivery field. Previous studies demonstrated that Pluronics sensitize MDR cancer cells resulting in increased cytotoxic activity of Dox, paclitaxel, and other drugs by 2–3 orders of magnitude. Pluronics can also prevent the development of MDR in vitro and in vivo. Additionally, promising results of clinical studies of Dox/Pluronic formulation reinforced the need to ascertain a thorough understanding of Pluronic effects in tumors. These effects are extremely comprehensive and appear on the level of plasma membranes, mitochondria, and regulation of gene expression selectively in MDR cancer cells. Moreover, it has been demonstrated recently that Pluronics can effectively deplete tumorigenic intrinsically drug-resistant cancer stem cells (CSC). Interestingly, sensitization of MDR and inhibition of drug efflux transporters is not specific or selective to Pluronics. Other amphiphilic polymers have shown similar activities in various experimental models. This review summarizes recent advances of understanding the Pluronic effects in sensitization and prevention of MDR.
Found 
Found 

Top-30

Journals

1
2
3
4
5
6
7
International Journal of Pharmaceutics
7 publications, 3.54%
Journal of Controlled Release
7 publications, 3.54%
Langmuir
7 publications, 3.54%
Journal of Molecular Liquids
6 publications, 3.03%
Polymers
5 publications, 2.53%
Molecular Pharmaceutics
5 publications, 2.53%
Biomaterials
4 publications, 2.02%
ACS applied materials & interfaces
3 publications, 1.52%
Pharmaceutics
3 publications, 1.52%
Journal of Colloid and Interface Science
3 publications, 1.52%
Macromolecular Bioscience
3 publications, 1.52%
ACS Nano
3 publications, 1.52%
Journal of Materials Chemistry B
3 publications, 1.52%
Pharmaceutical Research
2 publications, 1.01%
ACS Applied Polymer Materials
2 publications, 1.01%
Nanomedicine
2 publications, 1.01%
Nanomaterials
2 publications, 1.01%
Antioxidants
2 publications, 1.01%
Drug Delivery and Translational Research
2 publications, 1.01%
AAPS PharmSciTech
2 publications, 1.01%
Colloids and Surfaces B: Biointerfaces
2 publications, 1.01%
European Journal of Pharmaceutical Sciences
2 publications, 1.01%
Advanced Drug Delivery Reviews
2 publications, 1.01%
Colloids and Surfaces A: Physicochemical and Engineering Aspects
2 publications, 1.01%
Nanomedicine: Nanotechnology, Biology, and Medicine
2 publications, 1.01%
Journal of Drug Delivery Science and Technology
2 publications, 1.01%
Macromolecular Rapid Communications
2 publications, 1.01%
Advanced healthcare materials
2 publications, 1.01%
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
2 publications, 1.01%
1
2
3
4
5
6
7

Publishers

10
20
30
40
50
60
70
Elsevier
65 publications, 32.83%
American Chemical Society (ACS)
31 publications, 15.66%
Springer Nature
22 publications, 11.11%
Wiley
18 publications, 9.09%
MDPI
16 publications, 8.08%
Taylor & Francis
13 publications, 6.57%
Royal Society of Chemistry (RSC)
11 publications, 5.56%
Frontiers Media S.A.
2 publications, 1.01%
Public Library of Science (PLoS)
2 publications, 1.01%
Hindawi Limited
2 publications, 1.01%
Pleiades Publishing
1 publication, 0.51%
Bentham Science Publishers Ltd.
1 publication, 0.51%
Impact Journals
1 publication, 0.51%
SAGE
1 publication, 0.51%
Korean Society of Industrial Engineering Chemistry
1 publication, 0.51%
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.51%
American Physiological Society
1 publication, 0.51%
SciELO
1 publication, 0.51%
Cold Spring Harbor Laboratory
1 publication, 0.51%
Trans Tech Publications
1 publication, 0.51%
OAE Publishing Inc.
1 publication, 0.51%
AIP Publishing
1 publication, 0.51%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.51%
10
20
30
40
50
60
70
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
198
Share
Cite this
GOST |
Cite this
GOST Copy
Alakhova D. Y., Kabanov A. Pluronics and MDR Reversal: An Update // Molecular Pharmaceutics. 2014. Vol. 11. No. 8. pp. 2566-2578.
GOST all authors (up to 50) Copy
Alakhova D. Y., Kabanov A. Pluronics and MDR Reversal: An Update // Molecular Pharmaceutics. 2014. Vol. 11. No. 8. pp. 2566-2578.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1021/mp500298q
UR - https://doi.org/10.1021/mp500298q
TI - Pluronics and MDR Reversal: An Update
T2 - Molecular Pharmaceutics
AU - Alakhova, Daria Y
AU - Kabanov, A.A.
PY - 2014
DA - 2014/07/10
PB - American Chemical Society (ACS)
SP - 2566-2578
IS - 8
VL - 11
PMID - 24950236
SN - 1543-8384
SN - 1543-8392
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2014_Alakhova,
author = {Daria Y Alakhova and A.A. Kabanov},
title = {Pluronics and MDR Reversal: An Update},
journal = {Molecular Pharmaceutics},
year = {2014},
volume = {11},
publisher = {American Chemical Society (ACS)},
month = {jul},
url = {https://doi.org/10.1021/mp500298q},
number = {8},
pages = {2566--2578},
doi = {10.1021/mp500298q}
}
MLA
Cite this
MLA Copy
Alakhova, Daria Y., et al. “Pluronics and MDR Reversal: An Update.” Molecular Pharmaceutics, vol. 11, no. 8, Jul. 2014, pp. 2566-2578. https://doi.org/10.1021/mp500298q.